相似文献
1
Special issue: Recent advances in immunotherapy and immunoengineering.
Bioact Mater. 2025 Feb 28;48:529-530. doi: 10.1016/j.bioactmat.2025.01.038. eCollection 2025 Jun.
2
Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering.
Mol Ther Oncolytics. 2021 Oct 28;23:378-386. doi: 10.1016/j.omto.2021.10.010. eCollection 2021 Dec 17.
3
Mechanical Immunoengineering of T cells for Therapeutic Applications.
Acc Chem Res. 2020 Dec 15;53(12):2777-2790. doi: 10.1021/acs.accounts.0c00486. Epub 2020 Dec 1.
4
Immunoengineering the next generation of arthritis therapies.
Acta Biomater. 2021 Oct 1;133:74-86. doi: 10.1016/j.actbio.2021.03.062. Epub 2021 Apr 3.
5
Therapeutic synthetic and natural materials for immunoengineering.
Chem Soc Rev. 2024 Feb 19;53(4):1789-1822. doi: 10.1039/d3cs00805c.
6
Current Immunotherapy Strategies for Rheumatoid Arthritis: The Immunoengineering and Delivery Systems.
Research (Wash D C). 2023 Oct 17;6:0220. doi: 10.34133/research.0220. eCollection 2023.
7
Immunoengineering: An Emerging Field in Infectious Diseases.
J Infect Dis. 2025 Jul 30;232(1):28-35. doi: 10.1093/infdis/jiaf209.
8
Immunoengineering with biomaterials for enhanced cancer immunotherapy.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Jul;10(4):e1506. doi: 10.1002/wnan.1506. Epub 2018 Jan 14.
9
Immunoengineering has arrived.
J Biomed Mater Res A. 2021 Apr;109(4):397-403. doi: 10.1002/jbm.a.37041. Epub 2020 Aug 4.
10
Golden age of immunoengineering.
Immunol Rev. 2023 Nov;320(1):4-9. doi: 10.1111/imr.13283. Epub 2023 Oct 23.
本文引用的文献
1
Biomaterial-enhanced treg cell immunotherapy: A promising approach for transplant medicine and autoimmune disease treatment.
Bioact Mater. 2024 Apr 22;37:269-298. doi: 10.1016/j.bioactmat.2024.03.030. eCollection 2024 Jul.
2
High throughput screening of mesenchymal stromal cell morphological response to inflammatory signals for bioreactor-based manufacturing of extracellular vesicles that modulate microglia.
Bioact Mater. 2024 Mar 20;37:153-171. doi: 10.1016/j.bioactmat.2024.03.009. eCollection 2024 Jul.
3
Engineering LNPs with polysarcosine lipids for mRNA delivery.
Bioact Mater. 2024 Mar 16;37:86-93. doi: 10.1016/j.bioactmat.2024.03.017. eCollection 2024 Jul.
4
Immunotherapy targeting the obese white adipose tissue microenvironment: Focus on non-communicable diseases.
Bioact Mater. 2024 Feb 19;35:461-476. doi: 10.1016/j.bioactmat.2024.01.027. eCollection 2024 May.
5
Reversing cancer immunoediting phases with a tumor-activated and optically reinforced immunoscaffold.
Bioact Mater. 2024 Feb 3;35:228-241. doi: 10.1016/j.bioactmat.2024.01.026. eCollection 2024 May.
6
Convergence of nanomedicine and neutrophils for drug delivery.
Bioact Mater. 2024 Jan 27;35:150-166. doi: 10.1016/j.bioactmat.2024.01.022. eCollection 2024 May.
7
Rationally designed approaches to augment CAR-T therapy for solid tumor treatment.
Bioact Mater. 2023 Nov 26;33:377-395. doi: 10.1016/j.bioactmat.2023.11.002. eCollection 2024 Mar.
8
Engineered smart materials for RNA based molecular therapy to treat Glioblastoma.
Bioact Mater. 2023 Nov 27;33:396-423. doi: 10.1016/j.bioactmat.2023.11.007. eCollection 2024 Mar.
9
Exosome regulation of immune response mechanism: Pros and cons in immunotherapy.
Bioact Mater. 2023 Oct 4;32:124-146. doi: 10.1016/j.bioactmat.2023.09.018. eCollection 2024 Feb.
10
immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity.
Bioact Mater. 2023 Sep 26;32:12-27. doi: 10.1016/j.bioactmat.2023.09.007. eCollection 2024 Feb.
Zotero 插件